Condition: Fabry Disease · Sponsor: Shire
The main aim of this study is to learn more about the safety profile of Replagal. Participants will receive Replagal every 2 weeks at the clinic for about 1 year.
This description comes directly from the study's public registry record.
Takeda Contact · +1 866 842 5335 · ClinicalTransparency@takeda.com
Always discuss trial participation with your own doctor first.
| Institute of Child Health | Kolkata, India | Not Yet Recruiting |
| All India Institute of Medical Sciences (AIIMS) | New Delhi, India | Recruiting |
| Sir Gangaram Hospital | New Delhi, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05067868